Dapeng Li

发表

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

B. Haynes, M. Nussenzweig, R. Baric, 2021, bioRxiv.

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice

D. Weissman, B. Haynes, R. Baric, 2021, Science.

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice

D. Weissman, B. Haynes, R. Baric, 2021, Science.

SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment.

B. Haynes, P. Acharya, K. Saunders, 2021, Annual review of medicine.

RAB11FIP5-Deficient Mice Exhibit Cytokine-Related Transcriptomic Signatures

B. Haynes, P. Borrow, S. Xia, 2020, ImmunoHorizons.

Transcriptomic Signatures -Deficient Mice Exhibit Cytokine-Related RAB11FIP5

B. Haynes, P. Borrow, S. Xia, 2020 .

Nebulized mRNA‐Encoded Antibodies Protect Hamsters from SARS‐CoV‐2 Infection

B. Haynes, C. Zurla, J. Crowe, 2022, Advanced science.

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

B. Haynes, D. Montefiori, J. Theiler, 2021, Cell Host & Microbe.

Structural diversity of the SARS-CoV-2 Omicron spike

B. Haynes, D. Montefiori, P. Acharya, 2022, Molecular Cell.

Structural diversity of the SARS-CoV-2 Omicron spike

B. Haynes, P. Acharya, K. Janowska, 2022, bioRxiv.

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Rachel L. Spreng, D. Weissman, C. Woods, 2021, Nature.

Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine

D. Weissman, Haiyan Chen, Laura L. Sutherland, 2022, bioRxiv.

A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice

R. J. Edwards, B. Haynes, J. Mascola, 2021, Science Translational Medicine.

A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice

B. Haynes, J. Mascola, D. Montefiori, 2021, bioRxiv.

SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys

Rachel L. Spreng, D. Weissman, C. Woods, 2021, bioRxiv.

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates

C. Woods, Laura L. Sutherland, B. Haynes, 2021, bioRxiv.

Bafilomycin A1 inhibits SARS-CoV-2 infection in a human lung xenograft mouse model

Xiao Li, N. Jin, Yilong Zhu, 2023, Virology Journal.

Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity

B. Haynes, A. McMichael, P. Borrow, 2020, Communications Biology.

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

C. Woods, Laura L. Sutherland, B. Haynes, 2021, Cell.

Controlling the SARS-CoV-2 spike glycoprotein conformation

Mario J. Borgnia, Priyamvada Acharya, Barton F. Haynes, 2020, Nature Structural & Molecular Biology.

Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates

B. Haynes, D. Douek, N. Sullivan, 2021, Science Translational Medicine.

Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates

B. Haynes, D. Douek, N. Sullivan, 2021, bioRxiv.

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines

B. Haynes, D. Montefiori, J. Theiler, 2021, bioRxiv.

RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses

Ricardo Henao, C. Woods, G. Ginsburg, 2018, Cell.

Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity

B. Haynes, P. Acharya, K. Janowska, 2021, Science.

Cold sensitivity of the SARS-CoV-2 spike ectodomain

B. Haynes, D. Montefiori, R. Edwards, 2020, Nature Structural & Molecular Biology.

Cold sensitivity of the SARS-CoV-2 spike ectodomain

B. Haynes, D. Montefiori, R. Edwards, 2020, bioRxiv.

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

B. Haynes, M. Nussenzweig, R. Baric, 2021, Cell Reports.

Breakthrough infection evokes the nasopharyngeal innate immune responses established by SARS-CoV-2–inactivated vaccine

Xian-Chun Tang, Gang Xu, Zheng Zhang, 2023, Frontiers in Immunology.

Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions

B. Haynes, R. Baric, G. Ferrari, 2023, bioRxiv.

Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine

D. Weissman, Haiyan Chen, Laura L. Sutherland, 2022, Nature Communications.

Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity

B. Haynes, R. Edwards, P. Acharya, 2021, Science.

Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates

Laura L. Sutherland, R. Baric, S. Santra, 2023, bioRxiv.

A high affinity monoclonal antibody against HLA-E-VL9 enhances natural killer cell anti-tumor killing

P. Borrow, S. Brackenridge, W. Rountree, 2024, bioRxiv.

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

B. Haynes, M. Nussenzweig, R. Baric, 2021, Cell Reports.